0001127602-22-014711.txt : 20220517
0001127602-22-014711.hdr.sgml : 20220517
20220517132056
ACCESSION NUMBER: 0001127602-22-014711
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220516
FILED AS OF DATE: 20220517
DATE AS OF CHANGE: 20220517
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Farrell Michael J.
CENTRAL INDEX KEY: 0001485164
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-15317
FILM NUMBER: 22933473
MAIL ADDRESS:
STREET 1: C/O REMED INC
STREET 2: 9001 SPECTRUM CTR. BLVD.
CITY: SAN DIEGO,
STATE: CA
ZIP: 92123
FORMER NAME:
FORMER CONFORMED NAME: Farrell Michael
DATE OF NAME CHANGE: 20100224
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: RESMED INC
CENTRAL INDEX KEY: 0000943819
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 980152841
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0630
BUSINESS ADDRESS:
STREET 1: 9001 SPECTRUM CENTER BLVD.
CITY: SAN DIEGO
STATE: CA
ZIP: 92123
BUSINESS PHONE: 8587462400
MAIL ADDRESS:
STREET 1: 9001 SPECTRUM CENTER BLVD.
CITY: SAN DIEGO
STATE: CA
ZIP: 92123
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2022-05-16
0000943819
RESMED INC
RMD
0001485164
Farrell Michael J.
RESMED INC.
9001 SPECTRUM CENTER BLVD
SAN DIEGO
CA
92123
1
Chief Executive Officer
ResMed Common Stock
2022-05-16
4
M
0
5675
57.76
A
410935
D
ResMed Common Stock
2022-05-16
4
S
0
5675
196.607
D
405260
D
ResMed Common Stock
3880
I
Lisette and Michael Farrell Foundation
ResMed Common Stock
5090
I
Lisette and Michael Farrell Family Trust
ResMed Common Stock Options
57.76
2022-05-16
4
M
0
5675
0
D
2017-11-11
2023-11-16
ResMed Common Stock
5675
105615
D
The transaction was conducted under a Rule 10b5-1 plan.
This transaction was executed in multiple trades at prices ranging from $195.10 to $198.04. The price reported above reflects the weighted average sale price.
Includes 30.8872 shares of ResMed stock purchased on April 29, 2022, through the ResMed Employee Stock Purchase Plan.
Represents date options first became exercisable. Options vest 1/3 per year.
Michael J. Farrell, Chief Executive Officer
2022-05-17